TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
BIO-TECHNE Corp
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 24, 2026
$72.49−0.08 (-0.11%)
Close on Oct 19, 2026
- Market cap
- $11.40B
- P/E (TTM)
- 62.5
- Dividend yield
- 0.44%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
175M of 157M shares
Institutional holders
596
130 new, 112 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $437.19K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 7,859,928 | 5.00% | 13G (passive) | Mar 31, 2026 |
| Abigail P. Johnson | 12,754,784 | 8.10% | 13G (passive) amendment | Jun 30, 2026 |
| Vanguard Capital Management | 11,559,571 | 7.38% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 11,011,556 | 7.00% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TECH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 14,025,816 | 8.94% | $990.92M | +1,761,303 | 0.01% |
| FMR LLC | 12,794,784 | 8.16% | $903.95M | +4,894,856 | 0.04% |
| Vanguard Capital Management LLC | 10,218,558 | 6.52% | $721.94M | +38,849 | 0.02% |
| Goldman Sachs Group Inc | 7,343,324 | 4.68% | $518.81M | +5,399,790 | 0.05% |
| Hbk Investments L P | 6,825,000 | 4.35% | $482.19M | New | 4.71% |
| Vanguard Portfolio Management LLC | 6,506,360 | 4.15% | $459.67M | +26,023 | 0.02% |
| Morgan Stanley | 6,374,717 | 4.07% | $450.37M | −2,158,156 | 0.02% |
| State Street Corp | 5,980,370 | 3.81% | $422.51M | +111,974 | 0.01% |
| Geode Capital Management, LLC | 5,351,464 | 3.41% | $377.54M | +239,044 | 0.02% |
| Invesco Ltd. | 4,986,424 | 3.18% | $352.29M | +397,718 | 0.03% |
| Ruane, Cunniff & Goldfarb L.P. | 3,348,841 | 2.14% | $236.60M | −43,160 | 3.68% |
| Snyder Capital Management L P | 3,163,816 | 2.02% | $223.52M | +1,281,518 | 3.86% |
| Neuberger Berman Group LLC | 2,844,692 | 1.81% | $200.98M | −496,145 | 0.13% |
| Massachusetts Financial Services Co /Ma/ | 2,746,462 | 1.75% | $194.01M | −986,786 | 0.06% |
| Mairs & Power Inc | 2,700,698 | 1.72% | $190.80M | −49,584 | 1.75% |
| Capital Research Global Investors | 2,621,890 | 1.67% | $185.24M | −566,320 | 0.03% |
| UBS Group AG | 2,478,607 | 1.58% | $175.11M | −575,736 | 0.02% |
| Dimensional Fund Advisors LP | 2,253,512 | 1.44% | $159.22M | +280,376 | 0.03% |
| Whitebox Advisors LLC | 2,100,001 | 1.34% | $148.37M | New | 1.94% |
| Sumitomo Mitsui Trust Holdings, Inc. | 2,067,324 | 1.32% | $146.06M | +13,030 | 0.08% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 596 | 175M | 100.0% | 130 / 162 | 243 / 112 | 46M | 48M |
| Q1 2026 | 585 | 177M | 100.0% | 73 / 199 | 225 / 64 | 44M | 21M |
| Q4 2025 | 585 | 172M | 100.0% | 88 / 207 | 211 / 70 | 27M | 14M |
| Q3 2025 | 577 | 160M | 100.0% | 97 / 215 | 184 / 70 | 26M | 26M |
| Q2 2025 | 556 | 159M | 100.0% | 82 / 219 | 196 / 100 | 20M | 24M |
| Q1 2025 | 578 | 163M | 100.0% | 76 / 206 | 210 / 67 | 18M | 17M |
| Q4 2024 | 577 | 162M | 100.0% | 75 / 221 | 194 / 50 | 16M | 8M |
| Q3 2024 | 563 | 155M | 99.1% | 60 / 194 | 209 / 62 | 21M | 8M |
| Q2 2024 | 572 | 157M | 100.0% | 67 / 213 | 210 / 45 | 9M | 19M |
| Q1 2024 | 555 | 168M | 100.0% | 73 / 204 | 182 / 44 | 17M | 9M |
| Q4 2023 | 531 | 160M | 100.0% | 81 / 210 | 172 / 71 | 16M | 9M |
| Q3 2023 | 530 | 153M | 97.3% | 60 / 175 | 215 / 56 | 9M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TECH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Contrafund | 4,989,801 | 3.18% | $352.53M | 0.20% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,968,867 | 3.17% | $351.05M | 0.02% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 4,056,808 | 2.59% | $286.61M | 0.02% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 3,593,129 | 2.29% | $253.85M | 0.27% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,586,562 | 2.29% | $253.39M | 0.13% | Jun 30, 2026 |
| Invesco S&P 500 Equal Weight ETF | 3,550,177 | 2.26% | $255.93M | 0.27% | Jul 31, 2026 |
| Eaton Vance Atlanta Capital SMID-Cap Fund | 2,604,519 | 1.66% | $184.01M | 2.09% | Jun 30, 2026 |
| MFS Mid Cap Growth Fund | 2,330,856 | 1.49% | $120.46M | 0.87% | May 31, 2026 |
| iShares Core S&P 500 ETF | 2,160,586 | 1.38% | $152.65M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 2,071,188 | 1.32% | $146.33M | 0.31% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 2,002,138 | 1.28% | $103.47M | 0.01% | May 31, 2026 |
| Select Health Care Portfolio | 1,900,000 | 1.21% | $98.19M | 1.70% | May 31, 2026 |
| Neuberger Genesis Fund | 1,852,945 | 1.18% | $95.76M | 1.30% | May 31, 2026 |
| Select Medical Technology and Devices Portfolio | 1,640,000 | 1.05% | $84.76M | 2.85% | May 31, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,568,630 | 1.00% | $81.07M | 0.03% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kim Kelderman | Chief Executive Officer, Director | 82,762 | 0.05% | Aug 19, 2026 |
| James Hippel | CFO | 170,183 | 0.11% | Aug 19, 2026 |
| Shane Bohnen | SVP - General Counsel | 10,360 | 0.01% | Aug 19, 2026 |
| William Geist | PRESIDENT, PROTEIN SCIENCES | 24,943 | 0.02% | Aug 19, 2026 |
| Steven C. Crouse | President - Diag & Spatial Bi | 10,237 | 0.01% | Aug 19, 2026 |
| Matthew McManus | President - Diag & Spatial Bio | 7,691 | 0.00% | Feb 3, 2026 |
| John L. Higgins | Director | 77,254 | 0.05% | Sep 30, 2026 |
| Robert V. Baumgartner | Director | 56,884 | 0.04% | Sep 24, 2026 |
| Amy E. Herr | Director | 3,256 | 0.00% | Aug 19, 2026 |
| Rupert Vessey | Director | 10,987 | 0.01% | Nov 3, 2025 |
| Julie L. Bushman | Director | 8,775 | 0.01% | Nov 3, 2025 |
| Judith V. Klimovsky | Director | 3,782 | 0.00% | Nov 3, 2025 |
| Joseph D. Keegan | Director | 15,411 | 0.01% | Nov 3, 2025 |
| Alpna Seth | Director | 15,411 | 0.01% | Nov 3, 2025 |
| Roeland Nusse | Director | 44,559 | 0.03% | Aug 27, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John L. Higgins Director | Sep 28, 2026 | Tax withholding | −5,562 | $72.51 | $403.30K | 77,254 |
| John L. Higgins Director | Sep 28, 2026 | Option exercise | +15,940 | – | – | 82,816 |
| Robert V. Baumgartner Director | Sep 22, 2026 | Tax withholding | −5,559 | $72.55 | $403.31K | 56,884 |
| Robert V. Baumgartner Director | Sep 22, 2026 | Option exercise | +15,940 | – | – | 62,443 |
| William Geist PRESIDENT, PROTEIN SCIENCES | Aug 15, 2026 | Tax withholding | −1,976 | $72.40 | $143.06K | 24,943 |
| William Geist PRESIDENT, PROTEIN SCIENCES | Aug 15, 2026 | Option exercise | +6,416 | – | – | 26,919 |
| Kim Kelderman Chief Executive Officer, Director | Aug 15, 2026 | Tax withholding | −10,821 | $72.40 | $783.44K | 82,762 |
| Kim Kelderman Chief Executive Officer, Director | Aug 15, 2026 | Option exercise | +21,470 | – | – | 93,583 |
| Shane Bohnen SVP - General Counsel | Aug 15, 2026 | Option exercise | +4,350 | – | – | 11,703 |
| Shane Bohnen SVP - General Counsel | Aug 15, 2026 | Tax withholding | −1,343 | $72.40 | $97.23K | 10,360 |
| Amy E. Herr Director | Aug 15, 2026 | Tax withholding | −213 | $72.40 | $15.42K | 576 |
| Amy E. Herr Director | Aug 15, 2026 | Option exercise | +589 | – | – | 789 |
| Steven C. Crouse President - Diag & Spatial Bi | Aug 15, 2026 | Option exercise | +5,423 | – | – | 12,184 |
| Steven C. Crouse President - Diag & Spatial Bi | Aug 15, 2026 | Tax withholding | −1,947 | $72.40 | $140.96K | 10,237 |
| James Hippel CFO | Aug 15, 2026 | Tax withholding | −4,310 | $72.40 | $312.04K | 170,183 |
| James Hippel CFO | Aug 15, 2026 | Option exercise | +9,779 | – | – | 174,493 |
| James Hippel CFO | Jul 29, 2026 | Option exercise | +62,068 | $47.60 | $2.95M | 215,738 |
| James Hippel CFO | Jul 29, 2026 | Tax withholding | −51,024 | $72.03 | $3.68M | 164,714 |
| Kim Kelderman Chief Executive Officer, Director | Jul 28, 2026 | Tax withholding | −28,686 | $72.07 | $2.07M | 72,113 |
| Kim Kelderman Chief Executive Officer, Director | Jul 28, 2026 | Option exercise | +35,000 | $47.60 | $1.67M | 100,799 |
| Shane Bohnen SVP - General Counsel | Jul 23, 2026 | Tax withholding | −344 | $71.77 | $24.69K | 7,353 |
| Shane Bohnen SVP - General Counsel | Jul 23, 2026 | Option exercise | +448 | $47.60 | $21.32K | 7,697 |
| Steven C. Crouse President - Diag & Spatial Bi | Jun 2, 2026 | Tax withholding | −216 | $49.77 | $10.75K | 6,761 |
| Steven C. Crouse President - Diag & Spatial Bi | Jun 2, 2026 | Option exercise | +600 | – | – | 6,977 |
| Amy E. Herr Director | May 8, 2026 | Sale | −6,636 | $48.28 | $320.39K | 200 |
| Amy E. Herr Director | May 8, 2026 | Option exercise | +6,636 | $47.60 | $315.87K | 6,836 |
| Shane Bohnen SVP - General Counsel | May 5, 2026 | Tax withholding | −7,055 | $56.68 | $399.88K | 7,249 |
| Shane Bohnen SVP - General Counsel | May 5, 2026 | Option exercise | +8,400 | $47.60 | $399.84K | 14,304 |
| James Hippel CFO | May 5, 2026 | Tax withholding | −56,955 | $56.68 | $3.23M | 153,670 |
| James Hippel CFO | May 5, 2026 | Option exercise | +62,000 | $47.60 | $2.95M | 210,625 |
| Kim Kelderman Chief Executive Officer, Director | May 5, 2026 | Option exercise | +26,692 | $47.60 | $1.27M | 89,750 |
| Kim Kelderman Chief Executive Officer, Director | May 5, 2026 | Tax withholding | −23,951 | $56.68 | $1.36M | 65,799 |
| Steven C. Crouse President - Diag & Spatial Bi | May 1, 2026 | Tax withholding | −311 | $55.02 | $17.11K | 6,337 |
| Steven C. Crouse President - Diag & Spatial Bi | May 1, 2026 | Option exercise | +794 | – | – | 6,688 |
| Kim Kelderman Chief Executive Officer, Director | Apr 22, 2026 | Tax withholding | −1,363 | $58.58 | $79.84K | 63,058 |
| Kim Kelderman Chief Executive Officer, Director | Apr 22, 2026 | Option exercise | +11,344 | – | – | 64,421 |
| James Hippel CFO | Apr 22, 2026 | Option exercise | +62,000 | – | – | 204,722 |
| James Hippel CFO | Apr 22, 2026 | Tax withholding | −56,097 | $58.58 | $3.29M | 148,625 |
| Kim Kelderman Chief Executive Officer, Director | Apr 14, 2026 | Tax withholding | −32,088 | $58.66 | $1.88M | 53,077 |
| Kim Kelderman Chief Executive Officer, Director | Apr 14, 2026 | Option exercise | +36,500 | – | – | 85,165 |
| Shane Bohnen SVP - General Counsel | Apr 3, 2026 | Tax withholding | −740 | $53.13 | $39.32K | 5,904 |
| Shane Bohnen SVP - General Counsel | Apr 3, 2026 | Option exercise | +2,259 | – | – | 6,644 |
| Amy E. Herr Director | Feb 17, 2026 | Sale | −1,976 | $59.11 | $116.80K | 200 |
| Amy E. Herr Director | Feb 3, 2026 | Option exercise | +38 | – | – | 2,192 |
| Amy E. Herr Director | Feb 3, 2026 | Tax withholding | −16 | $64.63 | $1.03K | 2,176 |
| Matthew McManus President - Diag & Spatial Bio | Feb 1, 2026 | Tax withholding | −1,665 | $64.09 | $106.71K | 7,691 |
| Matthew McManus President - Diag & Spatial Bio | Feb 1, 2026 | Option exercise | +4,621 | – | – | 9,356 |
| William Geist PRESIDENT, PROTEIN SCIENCES | Nov 3, 2025 | Tax withholding | −4,520 | $62.57 | $282.82K | 20,503 |
| William Geist PRESIDENT, PROTEIN SCIENCES | Nov 3, 2025 | Option exercise | +9,911 | – | – | 25,023 |
| Kim Kelderman Chief Executive Officer, Director | Nov 3, 2025 | Tax withholding | −2,303 | $62.57 | $144.10K | 48,665 |
| James Hippel CFO | Nov 3, 2025 | Tax withholding | −11,865 | $62.57 | $742.39K | 142,722 |
| James Hippel CFO | Nov 3, 2025 | Option exercise | +13,159 | – | – | 143,042 |
| James Hippel CFO | Nov 3, 2025 | Option exercise | +11,545 | – | – | 154,587 |
| Rupert Vessey Director | Oct 30, 2025 | Award | +1,640 | – | – | 10,987 |
| Judith V. Klimovsky Director | Oct 30, 2025 | Award | +1,640 | – | – | 3,782 |
| Alpna Seth Director | Oct 30, 2025 | Award | +1,640 | – | – | 15,411 |
| Julie L. Bushman Director | Oct 30, 2025 | Award | +1,640 | – | – | 8,775 |
| John L. Higgins Director | Oct 30, 2025 | Award | +1,640 | – | – | 66,876 |
| Robert V. Baumgartner Director | Oct 30, 2025 | Award | +1,640 | – | – | 46,503 |
| Joseph D. Keegan Director | Oct 30, 2025 | Award | +1,640 | – | – | 15,411 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Molho Joshua Director | May 8, 2026 | 6,636 | $320.42K | May 8, 2026 | Exercise of options under a registered plan |
| Molho Joshua Director | Feb 17, 2026 | 1,976 | $116.79K | Feb 17, 2026 | Previously Exercised Options |
| V. Baumgartner4731 Bonita Bay Boulevard Robert Director | Aug 25, 2025 | 17,040 | $957.85K | Aug 25, 2025 | Exercise of options under a registered plan |
| Nusse Roeland Director | Aug 25, 2025 | 17,040 | $960.39K | Aug 25, 2025 | Stock Option Exercise |
| Molho Joshua Officer | Jun 9, 2025 | 1,280 | $63.70K | Jun 9, 2025 | Exercise of options under a registered plan |
| Molho Joshua Domestic Partner of Director | Feb 14, 2025 | 1,860 | $122.69K | Feb 14, 2025 | Restricted stock vesting under a registered plan |
| Kelderman Kim Director, Officer | Jan 27, 2025 | 13,392 | $1.03M | Jan 27, 2025 | Exercise of Stock Options |
| V. Baumgartner Robert Director | Aug 8, 2024 | 16,000 | $1.15M | Aug 8, 2024 | Exercise of options under a registered plan |
| L. Higgins John Director | May 14, 2024 | 4,000 | $335.38K | May 14, 2024 | Exercise of options under a registered plan |
| Roeland Nusse Director | Mar 7, 2024 | 10,400 | $800.63K | Mar 7, 2024 | Stock Option Exercise and Stock Dividends |
| Nusse Roeland Director | Aug 30, 2023 | 8,939 | $717.96K | Aug 30, 2023 | Exercise of options under a registered plan |
| Charles R. Kummeth Officer | Jul 21, 2023 | 80,000 | $7.07M | Jul 21, 2023 | Stock Award |
| Kummeth Charles Officer | Jun 6, 2023 | 50,000 | $4.15M | Jun 6, 2023 | Stock Option Exercise |